Claseprubart (DNTH103) - (EMERGE)

September 29, 2026: Dianthus Therapeutics (NASDAQ: DNTH) announced one oral and four poster presentations on claseprubart (DNTH103) at the AANEM Annual Meeting (September 29-October 2, 2026, Orlando).

CIDP / CAPTIVATE (Phase 3): The company highlighted an interim responder analysis from the first 40 participants completing unblinded Part A, showing a 75% response rate with consistent, clinically meaningful improvements across multiple measures of function and disability in patients with varied prior treatment experience. CAPTIVATE data will be presented October 1 (oral presentation #149) and in poster #149.

gMG / MaGic open-label extension (Phase 2): Dianthus said claseprubart showed sustained efficacy and a continued favorable safety profile in generalized myasthenia gravis. Additional gMG posters cover sustained safety/efficacy, minimal symptom expression, and mechanistic comparisons of upstream versus downstream complement blockade.

Regulatory/status: Claseprubart is investigational and not approved in any indication. The release states it received FDA Orphan Drug Designation for myasthenia gravis in May 2026.

Upcoming catalysts: top-line Phase 2 MoMeNtum data in multifocal motor neuropathy are expected in December 2026; an update on timing of top-line data from Part B of Phase 3 CAPTIVATE is expected by year-end 2026; top-line Phase 3 EMERGE results in gMG are expected in 2H 2028.